Clinical trials
Mutation clinical trials
Below are recruiting mutation clinical trials, each written for real people, not researchers. We’re tracking 714 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07750067RecruitingPhase 2
Combination therapy for advanced melanoma with NRAS mutation
This trial tests a combination of three drugs (tunlametinib, pucotenlimab, and hydroxychloroquine) for people with advanced melanoma that has a specific genetic change called NRAS. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Guangzhou, GuangdongAges 18 years+ - NCT07751991RecruitingPhase 1
Study of a new drug for relapsed AML with specific genetic changes
This trial tests a new drug for people with acute myeloid leukemia (AML) that has come back or hasn't responded to standard therapies, and whose leukemia has certain genetic markers. The drug may target these specific changes to help stop the cancer.
Duarte, CaliforniaAges 18 years+ - NCT06603376RecruitingPhase 2
Drug combo for BRAF-mutated advanced colorectal cancer
This trial tests a combination of four drugs (irinotecan liposome, fluorouracil, folinic acid, vermofenib, and cetuximab) as a first treatment for people with advanced colorectal cancer that has a specific BRAF V600E mutation. It aims to see if this combination can shrink tumors or slow their growth.
ShanghaiAges 18–80 - NCT07744529RecruitingPhase 1/Phase 2
Combination treatment for lung cancer spread to the lining of the brain
This trial tests a new combination of two drugs for people with a specific type of lung cancer that has spread to the lining of the brain and spinal cord. The treatment aims to target the cancer cells and may help improve symptoms and survival.
Hangzhou, ZhejiangAges 18 years+ - NCT07729982Recruiting
Study tracking vision changes in OPA1 optic atrophy
This study follows people with a genetic form of optic atrophy over time to understand how vision changes. It does not test a treatment but helps doctors learn more about the condition to improve care.
Munich, BavariaAges Any age - NCT05766098Recruiting
Genetic testing of papillary thyroid tumor samples
This trial studies the genetic “mutations” in papillary thyroid cancer tumors using tumor tissue. The goal is to better describe tumor genetic patterns, which may help researchers understand the disease.
Milan, MIAges Any age - NCT06180434Recruiting
Short-term outcomes of proton vs photon radiation for IDH-mutated gliomas
This study looks at the short-term results of proton and photon radiation therapy in people with IDH-mutated grade 2 or 3 gliomas. It compares the two types of radiation to see how well they work and what side effects might occur.
RotterdamAges 18 years+ - NCT06207656RecruitingPhase 2
Targeted therapy for BRAF V600E mutated colorectal cancer
This trial tests if combining three targeted drugs (cetuximab, encorafenib, and binimetinib) before surgery can shrink or control cancer in people with a specific BRAF V600E mutation and a stable (MSS) tumor. It focuses on colorectal cancer that is either already able to be removed or could become removable with treatment.
MadridAges 18 years+ - NCT04335292RecruitingPhase 2
Osimertinib then chemotherapy for EGFR-mutated lung cancer
This Phase 2 study tests a treatment sequence starting with osimertinib, then using chemotherapy after it. It is meant for people with EGFR-mutated advanced lung cancer whose disease has come back or progressed, including a “rechallenge” attempt with osimertinib.
Vancouver, British ColumbiaAges 18 years+ - NCT06653517RecruitingPhase 2
Targeted therapy before surgery for a type of jaw tumor
This trial tests whether taking two targeted drugs (dabrafenib and trametinib) before surgery can shrink a specific type of jaw tumor called ameloblastoma. The tumor must have a certain genetic change (BRAF V600E mutation) and require a large jaw surgery. The goal is to see if the drugs make surgery less extensive or more successful.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT07691827Recruiting
Study of sperm problems linked to inherited genetic mutation
This study is investigating a specific genetic mutation in the MT-ND1 gene that can be passed from mother to son and may cause sperm production problems. It compares men with severe sperm issues to those with normal sperm production to understand the genetic cause.
Guangzhou, GuangdongAges Any age - NCT07696832Recruiting
Ivonescimab as first treatment for advanced lung cancer
This trial studies ivonescimab alone as a first treatment for people with advanced non-small cell lung cancer (NSCLC) that tests positive for PD-L1 and doesn't have certain gene changes. The goal is to see if it works and is safe in everyday medical practice.
Guangzhou, GuangdongAges 18 years+ - NCT06663007RecruitingPhase 1/Phase 2
RC48 alone or with envafolimab for advanced prostate cancer with CDK12 changes
This trial tests a drug called RC48, alone or with envafolimab, for men with a specific type of advanced prostate cancer that has not responded to standard treatments. It aims to see if this combination can shrink tumors or slow disease progression.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT05424692Recruiting
Test tumor drug sensitivity to guide after-surgery colon cancer care
This study looks at whether testing a small tumor sample can identify which medicines are more likely to work for colorectal cancer after surgery. The results are used to help choose the best “after-surgery” treatment plan, when you have not had chemotherapy before surgery.
Beijing, Beijing MunicipalityAges 18–75 - NCT06533384RecruitingPhase 3
PARP inhibitor or chemo plus immunotherapy after surgery for high-risk TNBC
This trial tests whether adding a PARP inhibitor or capecitabine (chemo) to a PD-1 inhibitor (immunotherapy) after surgery helps prevent triple-negative breast cancer from coming back. It's for people with high-risk disease who have completed initial treatment.
Guangzhou, GuangdongAges 18–70 - NCT06674343RecruitingPhase 3
Furmonertinib for advanced lung cancer with EGFR mutations
This trial tests a higher dose of furmonertinib (160mg) as a first treatment for advanced non-small cell lung cancer that has specific EGFR mutations (19Del or L858R). It aims to see if this drug can help shrink tumors and delay disease progression.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07655622RecruitingPhase 1/Phase 2
Vebreltinib and furmonertinib for advanced EGFR-mutant lung cancer with high PD-L1
This trial tests a combination of two targeted drugs, vebreltinib and furmonertinib, for people with advanced non-small cell lung cancer that has an EGFR mutation and high levels of a protein called PD-L1. It may be an option for those who have not yet had treatment for advanced disease.
Nanchang, JianxiAges 18–75 - NCT07660627Recruiting
ctDNA test for tracking cancer after treatment
This trial uses a blood test to find tiny bits of tumor DNA after treatment. It helps doctors see if any cancer remains, which could guide next steps for people with esophageal, stomach, or pancreatic cancer.
BrnoAges Any age - NCT07646600Recruiting
Natural History Study of BAG3 Heart Disease in Chinese Adults
This study follows adults with a specific genetic mutation (BAG3) that causes heart muscle weakness. Researchers will track how the disease develops over time to better understand it and help improve future treatments.
BeijingAges 18 years+ - NCT07640789RecruitingPhase 3
BL-B01D1 plus osimertinib for advanced lung cancer after chemotherapy
This study tests whether adding a new drug called BL-B01D1 to osimertinib (a targeted lung cancer medicine) works better than osimertinib alone. You may qualify if you have advanced lung cancer with an EGFR mutation that didn't get worse after chemotherapy and radiation treatment.
Jinan, ShandongAges 18–75 - NCT07642024RecruitingPhase 2/Phase 3
BL-B01D1 Plus Osimertinib Before Surgery for EGFR-Mutated Lung Cancer
This trial tests a combination of two drugs (BL-B01D1 and osimertinib) given before surgery to shrink EGFR-mutated lung tumors. The goal is to help make surgery more successful and improve outcomes for patients with this type of non-small cell lung cancer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07642908Recruiting
Brain imaging study of Parkinson's disease with LRRK2 gene mutations
This research study uses advanced MRI brain imaging to understand how a specific gene mutation (LRRK2) affects certain brain chemicals in people with Parkinson's disease. The goal is to learn more about how this genetic form of Parkinson's works, which could help develop better treatments.
Ann Arbor, MichiganAges 45 years+ - NCT06269211RecruitingPhase 2
Immunotherapy before surgery for EGFR-mutated lung cancer
This trial tests whether giving an immunotherapy drug (toripalimab) before surgery can help people with a specific type of lung cancer (EGFR-mutated, PD-L1 positive) that can be removed. The goal is to see if it improves treatment results compared to surgery alone.
Guangzhou, GuangdongAges 18 years+ - NCT06573073Recruiting
Lung cancer test for EGFR T790M mutation
This trial tests a new blood test that can detect a specific genetic change (EGFR T790M) in advanced lung cancer. It aims to see if the test works well for guiding treatment decisions.
TaipeiAges 18 years+
Hear when a new Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for mutation?
- Yes. Clin2 currently lists 714 recruiting mutation studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a mutation trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a mutation trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.